Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disseminated intravascular coagulation.

Hideo Wada1

  • 1Department of Laboratory Medicine, Mie University School of Medicine, 2-174, Edobashi, Tsu, Mie-ken 514-8507, Japan. wadahide@clin.medic.mie-u.ac.jp

Clinica Chimica Acta; International Journal of Clinical Chemistry
|May 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usefulness of Clot Waveform Analysis-Activated Thromboplastin Time (APTT) for Diagnosing Thrombotic Diseases.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

The C3 p.Ile1157Thr mutation associated with atypical hemolytic uremic syndrome, particularly in Japan, does not lead to disease development in several mouse models.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Recognizing Coagulation Disorders in Sepsis in the Emergency Room: A Narrative Review.

Journal of clinical medicine·2026
Same author

Evaluation of Autoimmune FVIII Inhibitor Using Clot Waveform Analysis in Emicizumab-Treated Patients.

Journal of clinical medicine·2026
Same author

Diagnostic and Prognostic Evaluation of Disseminated Intravascular Coagulation Using the Disseminated Intravascular Coagulation Index.

Journal of clinical medicine·2025
Same author

Factors influencing antithrombin activity following supplementation in sepsis-associated disseminated intravascular coagulation.

Thrombosis journal·2025

Disseminated intravascular coagulation (DIC) diagnosis relies on lab tests for hemostatic abnormalities, with distinct criteria for overt-DIC but not non-overt-DIC. Activated protein C and low-molecular-weight heparin show promise for DIC treatment.

Area of Science:

  • Hematology
  • Pathophysiology
  • Clinical Diagnostics

Background:

  • Disseminated intravascular coagulation (DIC) is a complex syndrome characterized by widespread activation of coagulation and fibrinolysis.
  • Historically diagnosed via microthrombi detection, current methods focus on laboratory assessment of hemostatic abnormalities.
  • DIC results from an imbalance between procoagulant and anticoagulant factors, leading to hypercoagulability and hyperfibrinolysis.

Purpose of the Study:

  • To review the diagnostic approaches for disseminated intravascular coagulation (DIC).
  • To differentiate between overt-DIC and non-overt-DIC stages.
  • To explore potential therapeutic strategies for DIC.

Main Methods:

  • Review of current diagnostic criteria for overt-DIC, including International Society of Thrombosis Haemostasis (ISTH) guidelines.

Related Experiment Videos

  • Discussion of the challenges in diagnosing non-overt-DIC due to lack of established criteria.
  • Examination of emerging treatment modalities for DIC.

    • Main Results:

    • Overt-DIC diagnosis is guided by established criteria, while non-overt-DIC lacks specific diagnostic standards.
    • Laboratory assessment of hemostatic abnormalities is central to current DIC diagnosis.
    • Limited evidence-based treatments exist, but activated protein C (APC) and low-molecular-weight heparin show therapeutic potential.

    Conclusions:

    • Accurate diagnosis of DIC, particularly the non-overt stage, remains a clinical challenge.
    • Further research is needed to establish diagnostic criteria for non-overt-DIC.
    • Activated protein C (APC) and low-molecular-weight heparin represent promising avenues for DIC management.